Cited by 793Immune cells in cancerImmunotherapy and Immune ResponsesCancer Immunotherapy and Biomarkers

The DOI matches its Crossref record; 30 of the 31 references it cites were found in a registry or an index.

A New Population of Myeloid-Derived Suppressor Cells in Hepatocellular Carcinoma Patients Induces CD4+CD25+Foxp3+ T Cells

Open access

Hoechst, Bastian, Ormandy, Lars A., Ballmaier, Matthias, Lehner, Frank, Krüger, Christine, Manns, Michael P., Greten, Tim F., Korangy, Firouzeh·2008·Gastroenterology

DOI 10.1053/j.gastro.2008.03.020

Open this paper in CoChat — free account Open PDF

Abstract

Background & aims Several studies have shown that development of hepatocellular carcinoma (HCC) generates a number of immune suppressive mechanisms in these patients. Myeloid-derived suppressor cells (MDSC) are a heterogeneous population of cells that have been shown to inhibit T-cell responses in tumor-bearing mice, but little is known about these cells in humans owing to a lack of specific markers. In this study, we have investigated the frequency and function of a new population of MDSC denoted here as CD14(+)HLA-DR(-/low) in HCC patients. We have also identified a novel, MDSC-mediated immune regulatory pathway in these patients.Methods We have directly isolated and characterized MDSCs for phenotype and function from peripheral blood (n = 111) and tumor (n = 12) of patients with HCC.Results The frequency of CD14(+)HLA-DR(-/low) cells in peripheral blood mononuclear cells (PBMC) from HCC patients was significantly increased in comparison with healthy controls. CD14(+) HLA-DR(-/low) cells were unable to stimulate an allogeneic T-cell response, suppressed autologous T-cell proliferation, and had high arginase activity, a hallmark characteristic of MDSC. Most important, CD14(+)HLA-DR(-/low) cells from HCC patients induced a CD4(+)CD25(+)Foxp3(+) regulatory T-cell population when cocultured with autologous T cells.Conclusion CD14(+)HLA-DR(-/low) cells are a new population of MDSC increased in blood and tumor of HCC patients. We propose a new mechanism by which MDSC exert their immunosuppressive function, through the induction of CD4(+)CD25(+)Foxp3(+) regulatory T cells in cocultured CD4(+) T cells. Understanding the mechanism of action of MDSC in HCC patients is important in the design of effective immunotherapeutic protocols.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1053/j.gastro.2008.03.020

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
Regulatory T cells, tumour immunity and immunotherapy
Zou, W. (2006) · Nature reviews. Immunology · doi:10.1038/nri1806 · Cited by 2,135
Induction of Interleukin 10–Producing, Nonproliferating Cd4+ T Cells with Regulatory Properties by Repetitive Stimulation with Allogeneic Immature Human Dendritic Cells
Jonuleit, H., Schmitt, E., Schuler, G., Knop, J., & Enk, A. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.9.1213 · Cited by 1,538
Immune surveillance of tumors
Swann, J. B., & Smyth, M. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31405 · Cited by 1,518
Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host
Huang, B., Pan, P.-Y., Li, Q., Sato, A. I., Levy, D. E., Bromberg, J., Divino, C. M., & Chen, S.-H. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1299 · Cited by 1,435
Increased Production of Immature Myeloid Cells in Cancer Patients: A Mechanism of Immunosuppression in Cancer
Almand, B., Clark, J. I., Nikitina, E., van Beynen, J., English, N. R., Knight, S. C., Carbone, D. P., & Gabrilovich, D. I. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.1.678 · Cited by 1,340
Arginase I Production in the Tumor Microenvironment by Mature Myeloid Cells Inhibits T-Cell Receptor Expression and Antigen-Specific T-Cell Responses
Rodriguez, P. C., Quiceno, D. G., Zabaleta, J., Ortiz, B., Zea, A. H., Piazuelo, M. B., Delgado, A., Correa, P., Brayer, J., Sotomayor, E. M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0465 · Cited by 1,276
Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer
Nagaraj, S., Gupta, K., Писарев, В. М., Kinarsky, L., Sherman, S., Kang, L., Herber, D. L., Schneck, J. P., & Gabrilovich, D. I. (2007) · Nature Medicine · doi:10.1038/nm1609 · Cited by 1,176
Intratumoral Balance of Regulatory and Cytotoxic T Cells Is Associated With Prognosis of Hepatocellular Carcinoma After Resection
Gao, Q., Qiu, S., Fan, J., Zhou, J., Wang, X., Xiao, Y., Xu, Y., Li, Y., & Tang, Z. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.4565 · Cited by 1,134
Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients.
Schmielau, J., & Finn, O. J. (2001) · PubMed · Cited by 867

Show all 31 references

Sorted by citations

Items 201–300 of 790

Tumor-Related Exosomes Contribute to Tumor-Promoting Microenvironment: An Immunological Perspective
Chen, W., Jiang, J., Xia, W., & Huang, J. (2017) · Journal of Immunology Research · doi:10.1155/2017/1073947 · Cited by 108
Autophagy orchestrates the regulatory program of tumor-associated myeloid-derived suppressor cells
Alissafi, T., Hatzioannou, A., Mintzas, K., Barouni, R. M., Banos, A., Sormendi, S., Polyzos, A., Xilouri, M., Wielockx, B., Gogas, H. J., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci120888 · Cited by 109
Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumab
Santegoets, S. J. A. M., Stam, A. G. M., Lougheed, S. M., Gall, H. E., Jooss, K. U., Sacks, N., Hege, K. M., Lowy, I., Scheper, R. J., Gerritsen, W. R., et al. (2014) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-014-0031-3 · Cited by 107
Generation of myeloid-derived suppressor cells using prostaglandin E2
Obermajer, N., & Kaliński, P. (2012) · Transplantation Research · doi:10.1186/2047-1440-1-15 · Cited by 110
MIF Is Necessary for Late-Stage Melanoma Patient MDSC Immune Suppression and Differentiation
Yaddanapudi, K., Rendon, B. E., Lamont, G. J., Kim, E. J., Rayyan, N. A., Richie, J., Albeituni, S., Waigel, S. J., Wise, A. D., & Mitchell, R. A. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0070-t · Cited by 106
PKM2 promotes metastasis by recruiting myeloid-derived suppressor cells and indicates poor prognosis for hepatocellular carcinoma
Liu, W.-R., Tian, M., Yang, L., Lin, Y., Jin, L., Ding, Z., Shen, Y., Peng, Y., Gao, D., Zhou, J., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2749 · Cited by 107
Understanding tumour cell heterogeneity and its implication for immunotherapy in liver cancer using single-cell analysis
Heinrich, S., Craig, A. J., Ma, L., Heinrich, B., Greten, T. F., & Wang, X. W. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.11.036 · Cited by 105
Self-citation
Effect of First-Line Treatment on Myeloid-Derived Suppressor Cells’ Subpopulations in the Peripheral Blood of Patients with Non–Small Cell Lung Cancer
Koinis, F., Vetsika, E., Aggouraki, D., Skalidaki, E., Koutoulaki, A., Gkioulmpasani, M., Georgoulias, V., & Kotsakis, A. P. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.04.026 · Cited by 102
The innate and adaptive infiltrating immune systems as targets for breast cancer immunotherapy
Law, A. M. K., Lim, E., Ormandy, C. J., & Gallego‐Ortega, D. (2017) · Endocrine Related Cancer · doi:10.1530/erc-16-0404 · Cited by 103
Myeloid-Derived Suppressor Cells: General Characteristics and Relevance to Clinical Management of Pancreatic Cancer
Goedegebuure, P. S., Mitchem, J. B., Porembka, M. R., Tan, M. C. B., Belt, B. A., Wang‐Gillam, A., Gillanders, W. E., Hawkins, W. G., & Linehan, D. C. (2011) · Current Cancer Drug Targets · doi:10.2174/156800911796191024 · Cited by 104
Myeloid regulatory cells in tumor spreading and metastasis
Keskinov, A. A., & Shurin, M. R. (2014) · Immunobiology · doi:10.1016/j.imbio.2014.07.017 · Cited by 104
Myeloid‐derived suppressor cells as effectors of immune suppression in cancer
Pyzer, A. R., Cole, L., Rosenblatt, J. M., & Avigan, D. (2016) · International Journal of Cancer · doi:10.1002/ijc.30232 · Cited by 101
In vivoInhibition of Human CD19-Targeted Effector T Cells by Natural T Regulatory Cells in a Xenotransplant Murine Model of B Cell Malignancy
Lee, J., Hayman, E. G., Pegram, H. J., Santos, E. B., Heller, G., Sadelain, M., & Brentjens, R. J. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-0552 · Cited by 101
Adaptive immunity in the liver
Shuai, Z., Leung, M. W., He, X.-S., Zhang, W., Yang, G., Leung, P. S. C., & Gershwin, M. E. (2016) · Cellular and Molecular Immunology · doi:10.1038/cmi.2016.4 · Cited by 104
MDSCs in cancer: Conceiving new prognostic and therapeutic targets
Sanctis, F. D., Solito, S., Ugel, S., Molon, B., Bronte, V., & Marigo, I. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2015.08.001 · Cited by 101
Icaritin promotes tumor T‐cell infiltration and induces antitumor immunity in mice
Hao, H., Zhang, Q., Zhu, H., Wen, Y., Qiu, D., Xiong, J., Fu, X., Wu, Y., Meng, K., & Li, J. (2019) · European Journal of Immunology · doi:10.1002/eji.201948225 · Cited by 98
Liver Cancer Immunity
Ilyas, S. I., Wang, J., & El‐Khoueiry, A. B. (2020) · Hepatology · doi:10.1002/hep.31416 · Cited by 99
Immunosuppressive Effects of Myeloid-Derived Suppressor Cells in Cancer and Immunotherapy
Krishnamoorthy, M., Gerhardt, L., & Vareki, S. M. (2021) · Cells · doi:10.3390/cells10051170 · Cited by 100
Antigen specificity of immune suppression by myeloid-derived suppressor cells
Solito, S., Bronte, V., & Mandruzzato, S. (2011) · Journal of Leukocyte Biology · doi:10.1189/jlb.0111021 · Cited by 96
Myeloid-Derived Suppressor Cells Regulate Immune Response in Patients with Chronic Hepatitis B Virus Infection through PD-1–Induced IL-10
Huang, A., Zhang, B., Yan, W., Wang, B., Wei, H., Zhang, F., Wu, L., Fan, K., & Guo, Y. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1400849 · Cited by 94
Metformin blocks myeloid-derived suppressor cell accumulation through AMPK-DACH1-CXCL1 axis
Qin, G., Lian, J., Huang, L. J., Zhao, Q., Liu, S., Zhang, Z., Chen, X., Yue, D., Li, L., Li, F., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1442167 · Cited by 94
Origin and Functions of Tumor-Associated Myeloid Cells (TAMCs)
Sica, A., Porta, C., Morlacchi, S., Banfi, S., Strauss, L., Rimoldi, M., Totaro, M. G., & Riboldi, E. (2011) · Cancer Microenvironment · doi:10.1007/s12307-011-0091-6 · Cited by 96
IL-10 induces the development of immunosuppressive CD14+HLA-DRlow/− monocytes in B-cell non-Hodgkin lymphoma
Xiu, B., Lin, Y., Grote, D. M., Ziesmer, S. C., Gustafson, M. P., Maas, M. L., Zhang, Z., Dietz, A. B., Porrata, L. F., Novak, A. J., et al. (2015) · Blood Cancer Journal · doi:10.1038/bcj.2015.56 · Cited by 94
Myeloid-derived suppressor cells: mechanisms of action and recent advances in their role in transplant tolerance
Dilek, N., de Silly, R. V., Blancho, G., & Vanhove, B. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00208 · Cited by 93
The Immune Modulation Effect of Locoregional Therapies and Its Potential Synergy with Immunotherapy in Hepatocellular Carcinoma
Singh, P., Toom, S., Avula, A., Kumar, V., & Rahma, O. E. (2020) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s187121 · Cited by 93
Neutrophil diversity in inflammation and cancer
Carnevale, S., Ceglie, I. D., Grieco, G., Rigatelli, A., Bonavita, E., & Jaillon, S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1180810 · Cited by 96
The immunobiology of myeloid-derived suppressor cells in cancer
Motallebnezhad, M., Jadidi‐Niaragh, F., Qamsari, E. S., Bagheri, S., Gharibi, T., & Yousefi, M. (2015) · Tumor Biology · doi:10.1007/s13277-015-4477-9 · Cited by 95
Inhibition of arginase modulates T-cell response in the tumor microenvironment of lung carcinoma
Sosnowska, A., Chlebowska, J., Matryba, P., Pilch, Z., Greig, A., Wolny, A., Grzywa, T. M., Rydzyńska, Z., Sokołowska, O., Rygiel, T. P., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1956143 · Cited by 98
Cancer‐associated fibroblast‐targeted strategy enhances antitumor immune responses in dendritic cell‐based vaccine
Ohshio, Y., Teramoto, K., Hanaoka, J., Tezuka, N., Itoh, Y., Asai, T., Daigo, Y., & Ogasawara, K. (2014) · Cancer Science · doi:10.1111/cas.12584 · Cited by 92
HIV Type 1 gp120–Induced Expansion of Myeloid Derived Suppressor Cells Is Dependent on Interleukin 6 and Suppresses Immunity
Garg, A., & Spector, S. A. (2013) · The Journal of Infectious Diseases · doi:10.1093/infdis/jit469 · Cited by 91
Myeloid derived suppressor cells in physiological and pathological conditions: the good, the bad, and the ugly
Serafini, P. (2013) · Immunologic Research · doi:10.1007/s12026-013-8455-2 · Cited by 96
Myeloid‐Derived Suppressor Cells and Therapeutic Strategies in Cancer
Katoh, H., & Watanabe, M. (2015) · Mediators of Inflammation · doi:10.1155/2015/159269 · Cited by 91
Tumor-induced CD14+HLA-DR−/low myeloid-derived suppressor cells correlate with tumor progression and outcome of therapy in multiple myeloma patients
Wang, Z., Zhang, L., Wang, H., Xiong, S., Li, Y., Tao, Q., Xiao, W., Qin, H., Wang, Y., & Zhai, Z. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1646-4 · Cited by 90
Type 1 T Helper Cells Induce the Accumulation of Myeloid-Derived Suppressor Cells in the Inflamed Tgfb1 Knockout Mouse Liver
Cripps, J. G., Wang, J., Maria, A., Blumenthal, I., & Gorham, J. D. (2010) · Hepatology · doi:10.1002/hep.23841 · Cited by 90
Hepatitis B Surface Antigen Could Contribute to the Immunopathogenesis of Hepatitis B Virus Infection
Kondo, Y., Ninomiya, M., Kakazu, E., Kimura, O. S., & Shimosegawa, T. (2013) · ISRN Gastroenterology · doi:10.1155/2013/935295 · Cited by 89
Myeloid-Derived Suppressor Cells and Radiotherapy
Jiménez‐Cortegana, C., Galassi, C., Klapp, V., Gabrilovich, D. I., & Galluzzi, L. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-1105 · Cited by 88
Inflammation and liver tumorigenesis
Sun, B., & Karin, M. (2013) · Frontiers of Medicine · doi:10.1007/s11684-013-0256-4 · Cited by 90
Myeloid-derived suppressor cells in transplantation and cancer
Ochando, J., & Chen, S. (2012) · Immunologic Research · doi:10.1007/s12026-012-8335-1 · Cited by 86
Myeloid Cells Obtained from the Blood but Not from the Tumor Can Suppress T-cell Proliferation in Patients with Melanoma
Gros, A., Turcotte, S., Wunderlich, J. R., Ahmadzadeh, M., Dudley, M. E., & Rosenberg, S. A. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1108 · Cited by 86
Effect of transcatheter arterial chemoembolization on cellular immune function and regulatory T cells in patients with hepatocellular carcinoma
Liao, J., Xiao, J., Zhou, Y., Li, H., & Wang, C. (2015) · Molecular Medicine Reports · doi:10.3892/mmr.2015.4171 · Cited by 86
Myeloid-Derived Suppressor Cells: Paradoxical Roles in Infection and Immunity
Dai, J., Gazzar, M. E., Li, G. Y., Moorman, J. P., & Yao, Z. Q. (2014) · Journal of Innate Immunity · doi:10.1159/000368233 · Cited by 87
Understanding the Differentiation, Expansion, Recruitment and Suppressive Activities of Myeloid-Derived Suppressor Cells in Cancers
Lim, H. X., Kim, T. S., & Poh, C. L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103599 · Cited by 87
Tumor regulation of the tissue environment in the liver
Eggert, T., & Greten, T. F. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.005 · Cited by 86
Self-citation
Interaction Between MDSC and NK Cells in Solid and Hematological Malignancies: Impact on HSCT
Tumino, N., Pace, A. L. D., Besi, F., Quatrini, L., Vacca, P., & Moretta, L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.638841 · Cited by 84
Phase Ib Study of Immune Biomarker Modulation with Neoadjuvant Cetuximab and TLR8 Stimulation in Head and Neck Cancer to Overcome Suppressive Myeloid Signals
Shayan, G., Kansy, B., Gibson, S. P., Srivastava, R. M., Bryan, J. K., Bauman, J. E., Ohr, J. P., Kim, S., Duvvuri, U., Clump, D. A., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0357 · Cited by 84
The mechanism of the premetastatic niche facilitating colorectal cancer liver metastasis generated from myeloid-derived suppressor cells induced by the S1PR1–STAT3 signaling pathway
Lin, Q., Ren, L., Jian, M., Xu, P., Li, J., Zheng, P., Feng, Q., Yang, L., Ji, M., Wei, Y., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1922-5 · Cited by 86
Current perspectives on the tumor microenvironment in hepatocellular carcinoma
Santhakumar, C., Gane, E. J., Liu, K., & McCaughan, G. W. (2020) · Hepatology International · doi:10.1007/s12072-020-10104-3 · Cited by 83
Immune landscape of hepatocellular carcinoma microenvironment: Implications for prognosis and therapeutic applications
Cariani, E., & Missale, G. (2019) · Liver International · doi:10.1111/liv.14192 · Cited by 83
The Immunology of Hepatocellular Carcinoma
Lawal, G., Xiao, Y., Rahnemai‐Azar, A. A., Tsilimigras, D. I., Kuang, M., Bakopoulos, A., & Pawlik, T. M. (2021) · Vaccines · doi:10.3390/vaccines9101184 · Cited by 81
Complex Role of Regulatory T Cells (Tregs) in the Tumor Microenvironment: Their Molecular Mechanisms and Bidirectional Effects on Cancer Progression
Wang, Y., Li, J., Nakahata, S., & Iha, H. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137346 · Cited by 86
MDSCs in liver cancer: A critical tumor-promoting player and a potential therapeutic target
Ma, C., Zhang, Q., & Greten, T. F. (2021) · Cellular Immunology · doi:10.1016/j.cellimm.2021.104295 · Cited by 79
Self-citation
Immunity as Cornerstone of Non-Alcoholic Fatty Liver Disease: The Contribution of Oxidative Stress in the Disease Progression
Dallio, M., Sangineto, M., Romeo, M., Villani, R., Romano, A. D., Loguercio, C., Serviddio, G., & Federico, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22010436 · Cited by 77
Molecular Targets of Triple-Negative Breast Cancer: Where Do We Stand?
Newton, E. E., Mueller, L. E., Treadwell, S. M., Morris, C. A., & Machado, H. L. (2022) · Cancers · doi:10.3390/cancers14030482 · Cited by 83
MDSC in Mice and Men: Mechanisms of Immunosuppression in Cancer
Vanhaver, C., van der Bruggen, P., & Bruger, A. M. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10132872 · Cited by 77
Immunosuppressive CD14 + HLA-DR lo/neg monocytes are elevated in pancreatic cancer and “primed” by tumor-derived exosomes
Javeed, N., Gustafson, M. P., Dutta, S. K., Lin, Y., Bamlet, W. R., Oberg, A. L., Petersen, G. M., Chari, S. T., Dietz, A. B., & Mukhopadhyay, D. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1252013 · Cited by 76
The Role of Myeloid-Derived Suppressor Cells in Immune Ontogeny
Gantt, S. M., Gervassi, A. L., Jaspan, H. B., & Horton, H. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00387 · Cited by 75
CD11b+ Gr1+ bone marrow cells ameliorate liver fibrosis by producing interleukin-10 in mice
Suh, Y., Kim, J. K., Byun, J.-S., Yi, H., Lee, Y., Eun, H. S., Kim, S. Y., Han, K., Lee, K. S., Duester, G., et al. (2012) · Hepatology · doi:10.1002/hep.25817 · Cited by 76
Location, location, location: functional and phenotypic heterogeneity between tumor-infiltrating and non-infiltrating myeloid-derived suppressor cells
Maenhout, S. K., Thielemans, K., & Aerts, J. L. (2014) · OncoImmunology · doi:10.4161/21624011.2014.956579 · Cited by 74
Cancer-Associated Myeloproliferation: Old Association, New Therapeutic Target
Wilcox, R. A. (2010) · Mayo Clinic Proceedings · doi:10.4065/mcp.2010.0077 · Cited by 74
Hepatocellular Carcinoma: Novel Molecular Targets in Carcinogenesis for Future Therapies
Bertino, G., Demma, S., Ardiri, A., Proiti, M., Malaguarnera, G., Bertino, N., Malaguarnera, M., & Malaguarnera, M. (2014) · BioMed Research International · doi:10.1155/2014/203693 · Cited by 74
Retracted
Receptor‐Interacting Protein Kinase 3 Deficiency Recruits Myeloid‐Derived Suppressor Cells to Hepatocellular Carcinoma Through the Chemokine (C‐X‐C Motif) Ligand 1–Chemokine (C‐X‐C Motif) Receptor 2 Axis
Li, Y., Liu, Z., Wang, J., Yu, J., Li, Z., Yang, H., Tang, J., & Chen, Z. (2019) · Hepatology · doi:10.1002/hep.30676 · Cited by 73
CD15+/CD16low human granulocytes from terminal cancer patients: granulocytic myeloid-derived suppressor cells that have suppressive function
Choi, J., Suh, B., Ahn, Y., Kim, T. M., Lee, J., Lee, S., & Heo, D. S. (2011) · Tumor Biology · doi:10.1007/s13277-011-0254-6 · Cited by 73
The clinical and prognostic significance of CD14+HLA-DR−/low myeloid-derived suppressor cells in hepatocellular carcinoma patients receiving radiotherapy
Wang, D., An, G., Xie, S., Yao, Y., & Feng, G. (2016) · Tumor Biology · doi:10.1007/s13277-016-4916-2 · Cited by 73
PD-1+ and Foxp3+ T cell reduction correlates with survival of HCC patients after sorafenib therapy
Kalathil, S. G., Lugade, A. A., Miller, A., Iyer, R. V., & Thanavala, Y. M. (2016) · JCI Insight · doi:10.1172/jci.insight.86182 · Cited by 73
Immunosuppressive myeloid-derived suppressor cells are increased in splenocytes from cancer patients
Jordan, K. R., Kapoor, P., Spongberg, E., Tobin, R. P., Gao, D., Borges, V. F., & McCarter, M. D. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1953-z · Cited by 73
Expansion of myeloid-derived suppressor cells promotes differentiation of regulatory T cells in HIV-1+ individuals
Wang, L., Zhao, J., Ren, J. P., Wu, X. Y., Morrison, Z. D., Gazzar, M. E., Ning, S., Moorman, J. P., & Yao, Z. Q. (2016) · AIDS · doi:10.1097/qad.0000000000001083 · Cited by 72
Association of an increased frequency of CD14+HLA‐DRlo/neg monocytes with decreased time to progression in chronic lymphocytic leukaemia (CLL)
Gustafson, M. P., Abraham, R. S., Lin, Y., Wu, W., Gastineau, D. A., Zent, C. S., & Dietz, A. B. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.08902.x · Cited by 71
Myeloid-Derived Suppressor Cells as a Vehicle for Tumor-Specific Oncolytic Viral Therapy
Eisenstein, S. G., Coakley, B. A., Briley-Saebo, K. C., Ma, G., Chen, H.-M., Meseck, M. L., Ward, S., Divino, C. M., Woo, S. L. C., Chen, S., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-1597 · Cited by 74
Circulating CD14 + HLA‐DR −/low myeloid‐derived suppressor cells predicted early recurrence of hepatocellular carcinoma after surgery
Gao, X., Tian, L., Wu, J., Ma, X., Zhang, C., Zhou, Y., Sun, Y., Hu, B., Qiu, S., Zhou, J., et al. (2016) · Hepatology Research · doi:10.1111/hepr.12831 · Cited by 71
Heterogeneity Among Neutrophils
Garley, M., & Jabłońska, E. (2017) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-017-0476-4 · Cited by 75
Dendritic Cells Pulsed with Exosomes in Combination with PD-1 Antibody Increase the Efficacy of Sorafenib in Hepatocellular Carcinoma Model
Shi, S., Rao, Q., Zhang, C., Zhang, X., Qin, Y., & Niu, Z. (2018) · Translational Oncology · doi:10.1016/j.tranon.2018.01.001 · Cited by 73
Targeting myeloid-derived suppressor cells in the treatment of hepatocellular carcinoma: current state and future perspectives
Lu, L., Chang, C., & Hsu, C. (2019) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s159693 · Cited by 71
Augmentation of IFN-γ+ CD8+ T cell responses correlates with survival of HCC patients on sorafenib therapy
Kalathil, S. G., Hutson, A. D., Barbi, J. J., Iyer, R. V., & Thanavala, Y. M. (2019) · JCI Insight · doi:10.1172/jci.insight.130116 · Cited by 68
Effect of TLR Agonists on the Differentiation and Function of Human Monocytic Myeloid-Derived Suppressor Cells
Wang, J., Shirota, Y., Bayık, D., Shirota, H., Tross, D., Gulley, J. L., Wood, L. V., Berzofsky, J. A., & Klinman, D. M. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402004 · Cited by 69
Dendritic cell immunotherapy combined with gemcitabine chemotherapy enhances survival in a murine model of pancreatic carcinoma
Ghansah, T., Vohra, N. A., Kinney, K., Weber, A. M., Kodumudi, K. N., Springett, G. M., Sarnaik, A. A., & Pilon‐Thomas, S. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1407-9 · Cited by 68
Immune checkpoint blockade for the treatment of human hepatocellular carcinoma
Nishida, N., & Kudo, M. (2018) · Hepatology Research · doi:10.1111/hepr.13191 · Cited by 70
Increased circulating L in−/low CD 33+ HLA‐DR − myeloid‐derived suppressor cells in hepatocellular carcinoma patients
Shen, P., Wang, A., He, M., Wang, Q., & Zheng, S. (2013) · Hepatology Research · doi:10.1111/hepr.12167 · Cited by 67
Immune Suppression: The Hallmark of Myeloid Derived Suppressor Cells
Haile, L. A., Greten, T. F., & Korangy, F. (2012) · Immunological Investigations · doi:10.3109/08820139.2012.680635 · Cited by 67
Self-citation
Anti-Gr-1 antibody depletion fails to eliminate hepatic myeloid-derived suppressor cells in tumor-bearing mice
Ma, C., Kapanadze, T. G., Gamrekelashvili, J., Manns, M. P., Korangy, F., & Greten, T. F. (2012) · Journal of Leukocyte Biology · doi:10.1189/jlb.0212059 · Cited by 67
Self-citation
Increased circulating CD14(+)HLA-DR-/low myeloid-derived suppressor cells are associated with poor prognosis in patients with small-cell lung cancer
Tian, T., Gu, X., Zhang, B., Liu, Y., Yuan, C., Shao, L., Guo, Y., & Fan, K. (2015) · Cancer Biomarkers · doi:10.3233/cbm-150473 · Cited by 66
Programmed cell death‐1 blockade enhances response to stereotactic radiation in an orthotopic murine model of hepatocellular carcinoma
Friedman, D. J., Baird, J. R., Young, K. H., Cottam, B., Crittenden, M. R., Friedman, S. L., Gough, M. J., & Newell, P. (2016) · Hepatology Research · doi:10.1111/hepr.12789 · Cited by 66
Targeting tumor‐infiltrating Ly6G+ myeloid cells improves sorafenib efficacy in mouse orthotopic hepatocellular carcinoma
Chang, C. F., Yang, Y., Chiu, C.-J., Lu, L., Liao, C., Liang, C., Hsu, C., & Cheng, A. (2017) · International Journal of Cancer · doi:10.1002/ijc.31216 · Cited by 66
Myeloid‐derived suppressor cells induce regulatory T cells in chronically HBV infected patients with high levels of hepatitis B surface antigen and persist after antiviral therapy
Pal, S., Nandi, M., Dey, D., Chakraborty, B. C., Shil, A., Ghosh, S., Banerjee, S., Santra, A. K., Ahammed, S. K. M., Chowdhury, A., et al. (2019) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15226 · Cited by 70
Characterization of a whole blood assay for quantifying myeloid-derived suppressor cells
Apodaca, M. C., Wright, A. E., Riggins, A. M., Harris, W. P., Yeung, R. S. W., Yu, L., & Morishima, C. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0674-1 · Cited by 66
Tumour‐induced immune suppression: role of inflammatory mediators released by myelomonocytic cells
Mao, Y., Poschke, I. C., & Kiessling, R. W. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12229 · Cited by 68
A clinical and biological perspective of human myeloid-derived suppressor cells in cancer
Shipp, C., Speigl, L., Janssen, N., Martens, A., & Pawelec, G. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2278-y · Cited by 65
Myeloid-Derived Suppressor Cells as a Potential Therapy for Experimental Autoimmune Myasthenia Gravis
Li, Y., Tu, Z., Qian, S., Fung, J. J., Markowitz, S. D., Kusner, L. L., Kaminski, H. J., Lü, L., & Lin, F. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1400857 · Cited by 65
Increased Circulating Immunosuppressive CD14 + HLA-DR −/Low Cells Correlate with Clinical Cancer Stage and Pathological Grade in Patients with Bladder Carcinoma
Yuan, X.-K., Zhao, X.-K., Xia, Y.-C., Zhu, X., & Xiao, P. (2011) · Journal of International Medical Research · doi:10.1177/147323001103900424 · Cited by 65
Myeloid-derived Suppressor Cells (MDSCs) in Gliomas and Glioma-Development
Kohanbash, G., & Okada, H. (2012) · Immunological Investigations · doi:10.3109/08820139.2012.689591 · Cited by 65
Differential Phenotypes of Myeloid-Derived Suppressor and T Regulatory Cells and Cytokine Levels in Amnestic Mild Cognitive Impairment Subjects Compared to Mild Alzheimer Diseased Patients
Page, A. Y. L., Garneau, H., Dupuis, G., Frost, E. H., Larbi, A., Witkowski, J. M., Pawelec, G., & Fülöp, T. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00783 · Cited by 67
SPTBN1 inhibits inflammatory responses and hepatocarcinogenesis via the stabilization of SOCS1 and downregulation of p65 in hepatocellular carcinoma
Lin, L., Chen, S., Wang, H., Gao, B., Kallakury, B., Bhuvaneshwar, K., Cahn, K., Gusev, Y., Wang, X., Wu, Y., et al. (2021) · Theranostics · doi:10.7150/thno.49819 · Cited by 64
Regulatory T cells and immune escape in HCC: understanding the tumor microenvironment and advancing CAR-T cell therapy
Du, G., Dou, C., Sun, P., Wang, S., Liu, J., & Ma, L. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1431211 · Cited by 65
Radiotherapy combined with TLR7/8 activation induces strong immune responses against gastrointestinal tumors
Schölch, S., Rauber, C., Tietz, A., Rahbari, N. N., Bork, U., Schmidt, T., Kahlert, C., Haberkorn, U., Tomai, M. A., Lipson, K. E., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.3081 · Cited by 64
Myeloid cells in tumor inflammation
Schmid, M. C., & Varner, J. A. (2012) · Vascular Cell · doi:10.1186/2045-824x-4-14 · Cited by 67
Circulating immunosuppressive cells of prostate cancer patients before and after radical prostatectomy: Profile comparison
Brusa, D., Simone, M., Gontero, P., Spadi, R., Racca, P., Micari, J., Degiuli, M., Carletto, S., Tizzani, A., & Matera, L. (2013) · International Journal of Urology · doi:10.1111/iju.12086 · Cited by 63
Role of Foxp3-positive Tumor-infiltrating Lymphocytes in the Histologic Features and Clinical Outcomes of Hepatocellular Carcinoma
Mathai, A. M., Kapadia, M. J., Alexander, J., Kernochan, L. E., Swanson, P. E., & Yeh, M. M. (2012) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e31824e9b7c · Cited by 63
Improving cancer immunotherapy by targeting the STATe of MDSCs
de Haas, N., de Koning, C. C. H., Spilgies, L. M., de Vries, I. J. M., & Hato, S. V. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1196312 · Cited by 63
T lymphocytes in hepatocellular carcinoma immune microenvironment: insights into human immunology and immunotherapy.
Bian, J., Lin, J., Long, J., Xu, Y., Yang, X., Lu, X., Sang, X., & Zhao, H. (2020) · PubMed Central · Cited by 65
Natural Killer Cells and Regulatory T Cells Cross Talk in Hepatocellular Carcinoma: Exploring Therapeutic Options for the Next Decade
Bozward, A. G., Warricker, F., Oo, Y. H., & Khakoo, S. I. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.643310 · Cited by 65
Treatment with lenalidomide induces immunoactivating and counter-regulatory immunosuppressive changes in myeloma patients
Busch, A., Zeh, D., Janzen, V., Mügge, L.-O., Wolf, D. G. F., Fingerhut, L., Hahn‐Ast, C., Maurer, O., Brossart, P., & von Lilienfeld‐Toal, M. (2014) · Clinical & Experimental Immunology · doi:10.1111/cei.12343 · Cited by 62

Authors: Hoechst, B., Ormandy, L. A., Ballmaier, M., Lehner, F., Krüger, C., Manns, M. P., Greten, T. F., & Korangy, F.
Affiliations: Medizinische Hochschule Hannover (DE)
Corresponding author: Korangy, Firouzeh
ORCID: Ballmaier, Matthias
Lehner, Frank
Manns, Michael P.
Greten, Tim F.
Korangy, Firouzeh
Venue: Gastroenterology
Publisher: Elsevier BV
Published: 2008-07
Volume: 135
Issue: 1
Pages: 234-243
ISSN: 0016-5085 (ISSN-L)
DOI: 10.1053/j.gastro.2008.03.020
OpenAlex: W2059688175
Cited by: 793
References: 31
Citations by year: 2026: 18 · 2025: 20 · 2024: 25 · 2023: 34 · 2022: 50 · 2021: 46 · 2020: 53 · 2019: 40 · 2018: 39 · 2017: 60 · 2016: 54 · 2015: 65 · 2014: 55 · 2013: 65 · 2012: 59
FWCI: 15.02
Type: journal article
Language: en
Update notices: erratum (2011-08-01)
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Gastroenterology (publishedVersion)
PubMed (publishedVersion)
Funders: Deutsche Forschungsgemeinschaft (SFB-738)
Topics: Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Keywords: myeloid-derived suppressor cells, hepatocellular carcinoma, regulatory T cells, immunosuppression, arginase activity, CD4+CD25+Foxp3+ T cells, tumor immune microenvironment, T cell proliferation inhibition, cancer immunotherapy
MeSH terms: Aged, Arginase, Cell Communication, Cell Division, Cells, Cultured, Female, Flow Cytometry, Carcinoma, Hepatocellular, HLA-DR Antigens, Humans, Immune Tolerance, Liver Neoplasms, Male, Middle Aged, Biomarkers, CD4-Positive T-Lymphocytes, CD4 Antigens, Immunophenotyping, Interleukin-10, Lipopolysaccharide Receptors, Myeloid Cells, Forkhead Transcription Factors, Interleukin-2 Receptor alpha Subunit

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

A New Population of Myeloid-Derived Suppressor Cells in Hepatocellular Carcinoma Patients Induces CD4+CD25+Foxp3+ T Cells

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks